Evidence map›Paper›PMID 26265369›Full record

ArticleNature communications2015

Injectable cryogel-based whole-cell cancer vaccines.

Sidi A Bencherif, R Warren Sands, Omar A Ali, Weiwei A Li, Sarah A Lewin, Thomas M Braschler, Ting-Yu Shih, Catia S Verbeke, Deen Bhatta, Glenn Dranoff and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 3 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

181 citing papers in PubMed, 3 syntheses or guidelines pooled it, 407 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020
    Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Mechanomedicine.Nature reviews bioengineering · 2026
    Article
  17. Review
  18. Article
  19. Review
  20. Frontiers in immunology · 2026
    Review

121 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sidi A Bencherif1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA [3] Sorbonne University, UTC CNRS UMR 7338, Biomechanics and Bioengineering (BMBI), University of Technology of Compiègne, BP 20529, Rue Personne de Roberval, Compiègne 60205, France.
R Warren Sands1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA [3] University of Pittsburgh Medical Center Department of Medicine, Pittsburgh, Pennsylvania 15232, USA.
Omar A Ali1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA.
Weiwei A Li1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA.
Sarah A Lewin1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA.
Thomas M Braschler1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA [3] School of Engineering, LMIS4, Station 17, École polytechnique fédérale de Lausanne, Lausanne 1015, Switzerland.
Ting-Yu Shih1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA.
Catia S Verbeke1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA.
Deen Bhatta1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA.
Glenn DranoffDepartment of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA.
David J Mooney1] School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA [2] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA.
Harvard University · USDana-Farber Brigham Cancer Center · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008152 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ARDEHALI, HOSSEIN · 1987 to 2021
$24.0M
Programming dendritic cells in concert with morphagen delivery for periodontal reR01DE019917 · NIDCR · HARVARD UNIVERSITY · PI KAWAI, TOSHIHISA, MOONEY, DAVID J · 2009 to 2013
$3.5M
Programming antigen specific dendritic cells in situ for type 1 diabetes immunothF30DK088518 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SANDS, ROGER WARREN · 2010 to 2012
$126k
NCATS NIH HHS 1UL1 TR001102NCATS NIH HHS UL1 TR001102NIDCR NIH HHS 5R01DE019917-03NIDCR NIH HHS R01 DE019917NIDDK NIH HHS F30 DK088518NIDDK NIH HHS F30DK088518-03NIGMS NIH HHS T32 GM008152NIGMS NIH HHS T32-GM008152
6 · The paper itself

Abstract

A biomaterial-based vaccination system that uses minimal extracorporeal manipulation could provide in situ enhancement of dendritic cell (DC) numbers, a physical space where DCs interface with transplanted tumour cells, and an immunogenic context. Here we encapsulate GM-CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels. These cryogels are injected subcutaneously into mice to localize transplanted tumour cells and deliver immunomodulatory factors in a controlled spatio-temporal manner. These vaccines elicit local infiltrates composed of conventional and plasmacytoid DCs, with the subsequent induction of potent, durable and specific anti-tumour T-cell responses in a melanoma model. These cryogels can be delivered in a minimally invasive manner, bypass the need for genetic modification of transplanted cancer cells and provide sustained release of immunomodulators. Altogether, these findings indicate the potential for cryogels to serve as a platform for cancer cell vaccinations.

Indexed as

AnimalsCancer VaccinesCryogelsDendritic CellsFemaleMelanomaMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasms, ExperimentalT-LymphocytesCancer VaccinesCryogels

Identifiers

PMID26265369
PMCPMC4763944
OpenAlexW1854274831

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.